4.5 Article

Development of surface modified nanoparticles of curcumin for topical treatment of diabetic retinopathy: In vitro, ex vivo and in vivo investigation

出版社

ELSEVIER
DOI: 10.1016/j.jddst.2022.103835

关键词

Diabetic retinopathy; ELISA; Nanoparticles; Ophthalmology; PLGA 50; 50; VEGF

向作者/读者索取更多资源

Diabetic retinopathy is the most severe complication of diabetes that leads to blindness. The current treatment methods are invasive and associated with pain. This study developed surface-modified PLGA nanoparticles of Curcumin for targeted treatment of diabetic retinopathy. The optimized nanoparticles showed satisfactory results in in vitro and in vivo experiments.
Diabetic retinopathy (DR) is the worst microvascular complication of diabetes that results in blindness. Present treatment of DR is invasive and associated with pain and inflammation. There is a need to develop painless treatment. The surface-modified PLGA (50:50) nanoparticles of Curcumin, which is a peroxisome proliferator-activated receptor-gamma agonist, were prepared to target DR by topical administration. Nanoparticles were optimized by a 32 factorial design. The Concentration of PLGA and number of HPH cycles at fixed pressure were independent variables whereas particle size. PDI and % entrapment efficiency were the dependent variables. Batch F6 with particle size, PDI, and % EE 194.7 nm, 0.231, and 90% respectively was selected as the optimized batch. The optimized batch was further subjected to spray drying and evaluated for various parameters. Residual solvent analysis was carried out by Gas chromatography. In vitro drug release study showed a biphasic drug release pattern of 70.17 +/- 1.38% cumulative drug release at the end of 10 h. The release profile of curcumin from nanoparticles appeared to fit best with the Higuchi model. XRD study confirmed the molecular dispersion of the drug. The formulation showed satisfactory results in sterility testing, histology and isotonicity testing. In vivo study on rats showed dose dependent reduction in vascular endothelial growth factor (VEGF) concentration in vitreous fluid. Based on available evidences it can be concluded that the prepared formulation possesses great to diabetic

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据